For research use only. Not for therapeutic Use.
Capivasertib（Cat No.:I000539）is a potent and selective inhibitor of the serine/threonine protein kinase AKT, a key regulator in the PI3K/AKT/mTOR signaling pathway, which plays a central role in cell growth, survival, and metabolism. It is being investigated primarily for the treatment of cancers with aberrations in this pathway, such as breast cancer and prostate cancer. By targeting AKT, capivasertib disrupts tumor cell proliferation and enhances apoptosis. Its potential to overcome resistance to other therapies makes it a promising candidate in combination treatments for resistant or recurrent cancers.
| Catalog Number | I000539 |
| CAS Number | 1143532-39-1 |
| Synonyms | 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide |
| Molecular Formula | C21H25ClN6O2 |
| Purity | 98% |
| Target | AKT |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | Akt1：3 nM (IC50) |
| IUPAC Name | 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide |
| InChI | InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1 |
| InChIKey | JDUBGYFRJFOXQC-KRWDZBQOSA-N |
| SMILES | C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4 |
| Reference | [1]. Davies BR, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. |
